Signaling pathways implicated in PGF2α effects on Fgf2+/+ and Fgf2-/- osteoblasts

Journal of Cellular Physiology

Volumn 224, Issue 2, 2010, Pages 465-474

  Sabbieti, Maria Giovanna ^a   Agas, Dimitrios ^a   Marchetti, Luigi ^a   Santoni, Giorgio ^a   Amantini, Consuelo ^a   Xiao, Liping ^b   Menghi, Giovanna ^a   Hurley, Marja M ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN E; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEUTRALIZING ANTIBODY; PROSTAGLANDIN F2 ALPHA; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; CELL CYCLE PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; ISOPROTEIN; MDM2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALVARIA; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; ANIMAL; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PROTEIN TRANSPORT; SKULL; TIME; ULTRASTRUCTURE;

MUS;

ANIMALS; CELL CYCLE PROTEINS; DINOPROST; FIBROBLAST GROWTH FACTOR 2; MAP KINASE SIGNALING SYSTEM; MICE; OSTEOBLASTS; PROTEIN ISOFORMS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; SKULL; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953633021     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22143     Document Type: Article

References (46)

1. Agas D, Marchetti L, Menghi G, Materazzi S, Materazzi G, Capacchietti M, Hurley MM, Sabbieti MG. 2008. Anti-apoptotic Bcl-2 enhancing requires FGF-2/FGF receptor 1 binding in mouse osteoblasts. J Cell Physiol 214:145-152. (Pubitemid 350220068)
2. Alao JP. 2007. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 6:24.
3. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. 1994. Regulation of MDM2 expression by p53: Alternative promoters produce transcripts with non-identical translation potential. Genes Dev 8:1739-1749. (Pubitemid 24265781)
4. Brunet A, Pagès G, Pouysségur J. 1994. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 11:3379-3387. (Pubitemid 24338470)
5. Chang JK, Wu SC, Wang GJ, Cho MH, Ho ML. 2006. Effects of non-steroidal anti inflammatory drugs on cell proliferation and death in cultured epiphyseal-articular chondrocytes of fetal rats. Toxicology 228:111-123.
6. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. 2007. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97:557-561. (Pubitemid 47258446)
7. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
8. Davis RJ. 1993. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268:4553-14556.
9. Groth C, Lardelli M. 2002. The structure and function of vertebrate fibroblast growth factor receptor 1. Int J Dev Biol 46:393-400. (Pubitemid 36841006)
10. Herzinger T, Reed SI. 1998. Cyclin D3 is rate-limiting for the G1/S phase transition in fibroblasts. J Biol Chem 273:14958-14961. (Pubitemid 28272787)
11. Ho JS, Ma W, Mao DY, Benchimol S. 2005. p53-Dependent transcriptional repression of cmyc is required for G1 cell cycle arrest. Mol Cell Biol 25:7423-7431. (Pubitemid 41170106)
12. Hosokawa Y, Arnold A. 1996. Cyclin D1/PRAD1 as a central target in oncogenesis. J Lab Clin Med 127:246-252. (Pubitemid 126657304)
13. Hou Y, Gao F, Wang Q, Zhao J, Flagg T, Zhang Y, Deng X. 2007. Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex. J Biol Chem 282:9279-9287.
14. Hurley MM, Marie P, Florkiewicz R. 2002. Fibroblast growth factor and fibroblast growth factor receptor families. In: Bilezikian JP, Raisz LG, Rodan G, editors. Principles of bone biology. San Diego: Academic Press. pp 825-852.
15. Jiang M, Milner J. 2003. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev 17:832-837.
16. Jin Z, May WS, Gao F, Flagg T, Deng X. 2006. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 281:14446-14456.
17. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. 2003. Defective doublestrand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci USA 100:9974-9979.
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig R. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
19. Leach FS, Elledge SJ, Sherr CJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B. 1993. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 53:1986-1989.
20. Levy N, Yonish-Rouach E, Oren M, Kimchi A. 1993. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: Induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 13:7942-7952.
21. Li C-Y, Nagasawa H, Dahlberg WK, Little JB. 1995. Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. Oncogene 11:1885-1892.
22. Little JB, Nagasawa H, Keng PC, Yu Y, Li C-Y. 1995. Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J Biol Chem 270:11033-11036.
23. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 Is required for radiationinduced apoptosis in mouse thymocytes. Nature 362:847-849.
24. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970.
25. Marchetti L, Sabbieti MG, Agas D, Menghi M, Materazzi G, Menghi G, Hurley MM. 2006. PGF2α increases FGF-2 and FGFR2 trafficking in Py1a rat osteoblasts via clathrin independent and importin b dependent pathway. J Cell Biochem 97:1379-1392.
26. Montero A, Okada Y, Tomita M, Masato I, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM. 2000. Disruption of the fibroblast growth factor-2 results in decreased bone mass and bone formation. J Clin Invest 105:1085-1093. (Pubitemid 30217693)
27. Morgan DO. 1995. Principles of Cdk regulation. Nature 374:131-134.
28. Nijweide PJ, Burger EH, Feyen JH. 1986. Cells of bone: Proliferation, differentiation, and hormonal regulation. Physiol Rev 66:855-886. (Pubitemid 17181295)
29. Norbury C, Nurse P. 1992. Animal cell cycles and their control. Annu Rev Biochem 6:441-470.
30. Pilbeam CC, Harrison JR, Raisz LG. 1996. Prostaglandins and bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press. pp 715-728.
31. Reed SI. 1992. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol 8:529-561.
32. Rgimov N, Krauskop A, Navot N, Rotter V, Oren M, Aloni Y. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193. (Pubitemid 23129840)
33. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nuñez G, Clarke MF. 1994. c-Myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 21:5878-5882.
34. Sabbieti MG, Marchetti L, Abreu C, Montero A, Hand AR, Raisz LG, Hurley MM. 1999. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology 140:434-444. (Pubitemid 29011189)
35. Sabbieti MG, Marchetti L, Gabrielli MG, Menghi M, Materazzi S, Menghi G, Raisz LG, Hurley MM. 2005. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAP kinase. Cell Tissue Res 319: 267-278. (Pubitemid 40174520)
36. Saintigny Y, Dumay A, Lambert S, Lopez BS. 2001. A novel role for the Bcl-2 protein family: Specific suppression of the RAD51 recombination pathway. EMBO J 20:2596-2607. (Pubitemid 32452878)
37. Schroeder CP, Yang P, Newman RA, Lotan R. 2007. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol 6:183-192. (Pubitemid 46789718)
38. Shaulian E, Resnitzky D, Shifman O, Blandino G, Amsterdam A, Yayon A, Oren M. 1997. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 15:2717-2725.
39. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
40. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1cyclin dependent kinases. Genes Dev 9:1149-1163.
41. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
42. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507-4513. (Pubitemid 46815102)
43. Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. 1999. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 189:194-200. (Pubitemid 29448912)
44. Vaux DL, Cory S, Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442.
45. Youn CK, Cho HJ, Kim SH, Kim HB, Kim MH, Chang IY, Lee JS, Chung MH, Hahm KS, You HJ. 2005. Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat Cell Biol 7:137-147.
46. Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haundenschild CC, Moying Y, Coffin JD, Kong L, Kranias EG, Luo W, Boivin GP, Duffy JJ, Pawlowski SA, Doetschman T. 1998. Fibroblast growth factor 2 control of vascular tone. Nat Med 4:201-207.